Effects of sulfasalazine in axial spondyloarthritis on COVID-19 outcomes: real-life data from a single center

References

• Morens DM, Daszak P, Taubenberger JK. Escaping pandora’s Box - Another novel coronavirus. N Engl J Med. 2020;382(14):1293–1295.
   PubMed Web of Science ®Google Scholar
• Onder G, Rezza G, Brusaferro S. Case-Fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–1776.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected pneumonia in wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–2273.
   PubMed Web of Science ®Google Scholar
• Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50(SI-1):620–632.
   PubMed Web of Science ®Google Scholar
• Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol. 2020;2(6):335–343.
   PubMedGoogle Scholar
• Widhani A, Rengganis I, Susanto AJ, et al. Factors related to knowledge, perception, and practices towards COVID-19 among patients with autoimmune diseases: a multicenter online survey. Acta Med Indones. 2020;52(3):214–226.
   PubMed Web of Science ®Google Scholar
• Maggi E, Canonica GW, Moretta L. COVID-19: unanswered questions on immune response and pathogenesis. J Allergy Clin Immunol. 2020;146(1):18–22.
   PubMed Web of Science ®Google Scholar
• Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol. 2021;40(8):3079–3093.
   PubMed Web of Science ®Google Scholar
• D'Silva KM, Wallace ZS. COVID-19 and Disease-Modifying anti-rheumatic drugs. Curr Rheumatol Rep. 2021;23(5):28.
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Schafer M, Gianfrancesco MA, COVID-19 Global Rheumatology Alliance, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–942.
   PubMed Web of Science ®Google Scholar
• Feria-Garzon MG, Rugeles MT, Hernandez JC, et al. Sulfasalazine as an immunomodulator of the inflammatory process during HIV-1 infection. Int J Mol Sci. 2019;20(18):4476.
   PubMed Web of Science ®Google Scholar
• Hui DS, Lee N, Chan PK, et al. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018;150:202–216.
   PubMed Web of Science ®Google Scholar
• Khanna Sharma S, Kadiyala V, Naidu G, et al. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis. 2018;21(1):308–314.
   PubMed Web of Science ®Google Scholar
• Song IH, Hermann KG, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4):590–596.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American college of rheumatology/spondylitis association of america/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019; Oct71(10):1599–1613.
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006;33(4):722–731.
   PubMed Web of Science ®Google Scholar
• Jackson BR, Gold JAW, Natarajan P, et al. Predictors at admission of mechanical ventilation and death in an observational cohort of adults hospitalized with COVID-19. Clin Infect Dis. 2020;73(11):e4141–e4151.
   Web of Science ®Google Scholar
• Rizzello F, Calabrese C, Salice M, et al. COVID-19 in IBD: the experience of a single tertiary IBD center. Dig Liver Dis. 2021;53(3):271–276.
   PubMedGoogle Scholar
• Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70(4):725–732.
   PubMed Web of Science ®Google Scholar
• Carbo MJG, Spoorenberg A, Maas F, et al. Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors. PLoS One. 2018;13(4):e0196281.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Hsin-Hui H, et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. medRxiv. 2020;26(10):1636–1643.
   Google Scholar
• Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407–1409.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Brenner EJ, Zhang X, SECURE-IBD Advisory Committee including, et al. Physician practice patterns in holding inflammatory bowel disease medications due to COVID-19, in the SECURE-IBD registry. J Crohns Colitis. 2021;15(5):860–863.
   PubMed Web of Science ®Google Scholar
• Capelusnik D, Ramiro S, Schneeberger EE, et al. Peripheral arthritis and higher disease activity lead to more functional impairment in axial spondyloarthritis: longitudinal analysis from ESPAXIA. Semin Arthritis Rheum. 2021;51(3):553–558.
   PubMed Web of Science ®Google Scholar
• Lin KK, Sewell JL. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108(12):1824–1830.
   PubMed Web of Science ®Google Scholar
• Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481–491 e3.
   PubMed Web of Science ®Google Scholar
• Esatoglu SN, Tascilar K, Babaoğlu H, Turkish Society for Rheumatology COVID-19 Registry Investigators, et al. COVID-19 among patients with inflammatory rheumatic diseases. Front Immunol. 2021;12:651715.
   PubMed Web of Science ®Google Scholar
• Team CC-R. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, february 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–346.
   PubMed Web of Science ®Google Scholar